Can We Predict Osimertinib Resistance?

Video

There are certain indicators for patients with lung cancer who may progress on osimertinib.

There are certain characteristics that seem to have an effect on acquired resistance to osimertinib (Tagrisso) for patients with EGFR-positive non-small cell lung cancer (NSCLC), explained Niels Reinmuth, MD, PhD, head of the Thoracic Oncology Department at Asklepios Lung Clinic.

Those who progressed on the agent tended to have genetic amplifications or alterations, or changes in their signaling pathways, such as PI3k or BRAF.

While about 20 to 25% of patients can be molecularly identified, there is still work to be done for the rest of patient population.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
FDA Approves Tarlatamab for Extensive-Stage SCLC

FDA Approves Tarlatamab for Extensive-Stage SCLC

May 16th 2024
Article

Tarlatamab, a bispecific T-cell engager, was approved by the FDA for adults with extensive-stage small cell lung cancer.

The Vitals

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

November 15th 2023
Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Glecirasib Elicits Responses With Manageable Safety in Pretreated KRAS G12C Mutated NSCLC

Glecirasib Elicits Responses With Manageable Safety in Pretreated KRAS G12C Mutated NSCLC

May 14th 2024
Article

Glecirasib resulted in durable responses with a manageable safety profile for pretreated advanced non-small cell lung cancer with KRAS G12C mutations.

Oncology Nursing News

A Look Back at 2022 FDA Approvals in Oncology

January 2nd 2023
Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Oncology Drugs That Received FDA Approval in April 2024

Oncology Drugs That Received FDA Approval in April 2024

May 1st 2024
Article

Throughout April, the FDA approved drugs for the treatment of diseases including solid tumors, lung cancer, multiple myeloma, bladder cancer, and low-grade glioma.

Lung Cancer With COPD Leads to Poor Sleep, Quality of Life

Lung Cancer With COPD Leads to Poor Sleep, Quality of Life

April 29th 2024
Article

Poor sleep quality among those with lung cancer and COPD emphasize the need to develop effective assessment strategies.

© 2024 MJH Life Sciences

All rights reserved.